Business
Personalis Announces Updates to NeXT Platform™ Incorporating Additional Key Profiling Capabilities for Advancing Oncology Biomarkers
MENLO PARK, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the latest expansion of the
About this update from Personalis, Inc.
[{"type":"text","content":" MENLO PARK, Calif.--(BUSINESS WIRE)--\nPersonalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the latest expansion of the Personalis NeXT Platform® adding several new features that are key to the understanding of the interactions between the tumor and the immune system and how they may influence a cancer patient’s response to therapy.\n\nThe new and improved features include:\n\n\nInfiltrateID™, a sophisticated analytics module that leverages the augmented gene expression data from the NeXT Transcriptome™ to detect the presence of eight immune cell populations within a tumor sample\n\n\nRepertoireID™ now incorporates the characterization of the B-cell receptor repertoire, including the computing of isotype makeup, as a complement to the previously released T-cell receptor repertoire feature\n\n\nSHERPA™, further enhancing the performance of Personalis’ leading pan-allelic neoantigen prediction algorithm recently published in the Immunopeptidomics Special Issue of the journal Molecular & Cellular Proteomics\n\n\nPersonalis CMO and SVP of R&D, Richard Chen, MD, said, “With the ability to identify immune cell populations in the tumor, characterize the B-cell and T-cell receptor repertoires, and better predict neoantigens, we are further expanding the NeXT Platform for additional emerging oncology biomarkers. As we recently demonstrated with our NEOPS biomarker publication, combining both tumor and immune features into a composite biomarker can lead to better stratification of patient response to cancer therapy. These new NeXT Platform features open up opportunities to further enhance composite biomarkers like NEOPS.”\n\nThese advanced machine learning and algorithmic tools paired with the unique assay design of the NeXT Platform, further Personalis’ goal of providing the most comprehensive genomic tumor profiling platform available. The NeXT Platform consolidates multiple biomarker assays into one, enabling a seamless path from translational research to companion diagnostics development.\n\nAbout Personalis, Inc.\n\nPersonalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers a...